{"id":64628,"date":"2026-05-07T14:18:25","date_gmt":"2026-05-07T06:18:25","guid":{"rendered":"https:\/\/flcube.com\/?p=64628"},"modified":"2026-05-07T14:18:26","modified_gmt":"2026-05-07T06:18:26","slug":"kexing-pharmaceutical-launches-hkex-secondary-offering-innovative-biopharma-seeks-capital-to-advance-multimodal-pipeline","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=64628","title":{"rendered":"Kexing Pharmaceutical Launches HKEX Secondary Offering \u2013 Innovative Biopharma Seeks Capital to Advance Multimodal Pipeline"},"content":{"rendered":"\n<p><strong>Kexing Pharmaceutical<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/688136:SHA\">SHA: 688136<\/a>), an <strong>innovative biopharmaceutical company<\/strong> with an international footprint, released its <strong>prospectus for a secondary offering<\/strong> on the <strong>Hong Kong Stock Exchange<\/strong> this week. The company, which focuses on the <strong>research and development, manufacturing, and commercialization of recombinant proteins, antibodies, and targeted delivery therapies<\/strong>, reported <strong>RMB 1.534 billion (USD 225 million) in revenues<\/strong> and <strong>RMB 153 million (USD 22.5 million) in net profits<\/strong> for the previous fiscal year.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-corporate-profile-amp-financial-performance\">Corporate Profile &amp; Financial Performance<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>FY 2025<\/th><th>Notes<\/th><\/tr><\/thead><tbody><tr><td><strong>Total Revenues<\/strong><\/td><td>RMB 1.534 billion (USD 225 million)<\/td><td>Driven by proprietary and in-licensed commercial products<\/td><\/tr><tr><td><strong>Net Profits<\/strong><\/td><td>RMB 153 million (USD 22.5 million)<\/td><td>10% net profit margin demonstrating operational efficiency<\/td><\/tr><tr><td><strong>Primary Listing<\/strong><\/td><td>Shanghai Stock Exchange STAR Market (SHA: 688136)<\/td><td>Seeking secondary listing on Hong Kong Stock Exchange<\/td><\/tr><tr><td><strong>Business Focus<\/strong><\/td><td>Recombinant proteins, antibodies, targeted delivery therapies<\/td><td>Vertically integrated R&amp;D, manufacturing, and commercialization<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-commercial-portfolio\">Commercial Portfolio<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-proprietary-products-4\">Proprietary Products (4)<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>SINOGEN<\/strong>: Recombinant human interferon \u03b11b<\/li>\n\n\n\n<li><strong>EPOSINO<\/strong>: Human erythropoietin<\/li>\n\n\n\n<li><strong>WHITE-C<\/strong>: Human granulocyte colony-stimulating factor<\/li>\n\n\n\n<li><strong>CLOBICO<\/strong>: Combined clostridium butyricum and bacillus coagulans<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-in-licensed-products\">In-Licensed Products<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Apexelsin<\/strong>: Paclitaxel (albumin-bound)<\/li>\n\n\n\n<li><strong>Reminton<\/strong>: Infliximab<\/li>\n<\/ul>\n\n\n\n<p>This diversified commercial portfolio provides stable cash flow to support the company&#8217;s innovative pipeline development while establishing market presence across multiple therapeutic areas.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-pipeline-highlights-next-generation-therapeutics\">Pipeline Highlights \u2013 Next-Generation Therapeutics<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Candidate<\/th><th>Modality<\/th><th>Stage<\/th><th>Innovation<\/th><\/tr><\/thead><tbody><tr><td><strong>GB18<\/strong><\/td><td>GDF15 monoclonal antibody<\/td><td>Preclinical\/early clinical<\/td><td>Novel target for metabolic and inflammatory conditions<\/td><\/tr><tr><td><strong>GB23<\/strong><\/td><td>PD-1\/GPC3\/IFN trispecific antibody fusion protein<\/td><td>Preclinical\/early clinical<\/td><td>Multifunctional approach combining checkpoint inhibition, tumor targeting, and immune stimulation<\/td><\/tr><tr><td><strong>GB25<\/strong><\/td><td>CD3\/CDH17\/CDH17 bispecific tri-specific T-cell engager<\/td><td>Preclinical\/early clinical<\/td><td>Advanced T-cell redirection technology with dual CDH17 targeting<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>The pipeline reflects Kexing&#8217;s strategic focus on <strong>complex, multimodal biologics<\/strong> that address unmet needs through innovative engineering approaches beyond conventional monoclonal antibodies.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-rationale-amp-market-opportunity\">Strategic Rationale &amp; Market Opportunity<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Dual-Listing Strategy<\/strong>: The <strong>Hong Kong secondary offering<\/strong> provides access to international capital markets and enhances liquidity for global investors, supporting the company&#8217;s international expansion ambitions.<\/li>\n\n\n\n<li><strong>Pipeline Funding<\/strong>: Proceeds will accelerate development of the <strong>advanced pipeline candidates<\/strong>, particularly the novel trispecific and T-cell engager platforms that require significant R&amp;D investment.<\/li>\n\n\n\n<li><strong>Manufacturing Scale<\/strong>: As a vertically integrated biopharma with established <strong>recombinant protein and antibody manufacturing capabilities<\/strong>, Kexing is well-positioned to control costs and ensure supply chain security.<\/li>\n\n\n\n<li><strong>China Biotech Ecosystem<\/strong>: The company leverages China&#8217;s robust biopharmaceutical infrastructure while maintaining international standards, creating competitive advantages in both domestic and global markets.<\/li>\n<\/ul>\n\n\n\n<p>The secondary offering represents a strategic milestone in Kexing&#8217;s evolution from a commercial-stage biopharma to a globally competitive innovator with a differentiated pipeline of next-generation biologics.<\/p>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding capital raising, pipeline development, and financial performance. Actual results may differ due to risks including market conditions, regulatory approvals, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/sehk26050602892_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of sehk26050602892_c.\"><\/object><a id=\"wp-block-file--media-5f28a6ef-a2fd-48e1-9980-c0ce2c85012d\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/sehk26050602892_c.pdf\">sehk26050602892_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/sehk26050602892_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-5f28a6ef-a2fd-48e1-9980-c0ce2c85012d\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Kexing Pharmaceutical (SHA: 688136), an innovative biopharmaceutical company with an international footprint, released its prospectus&#8230;<\/p>\n","protected":false},"author":1,"featured_media":64630,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[1],"tags":[3625,1229],"class_list":["post-64628","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized","tag-kexing-biopharm","tag-sha-688136"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Kexing Pharmaceutical Launches HKEX Secondary Offering \u2013 Innovative Biopharma Seeks Capital to Advance Multimodal Pipeline - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Kexing Pharmaceutical (SHA: 688136), an innovative biopharmaceutical company with an international footprint, released its prospectus for a secondary offering on the Hong Kong Stock Exchange this week. The company, which focuses on the research and development, manufacturing, and commercialization of recombinant proteins, antibodies, and targeted delivery therapies, reported RMB 1.534 billion (USD 225 million) in revenues and RMB 153 million (USD 22.5 million) in net profits for the previous fiscal year.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=64628\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Kexing Pharmaceutical Launches HKEX Secondary Offering \u2013 Innovative Biopharma Seeks Capital to Advance Multimodal Pipeline\" \/>\n<meta property=\"og:description\" content=\"Kexing Pharmaceutical (SHA: 688136), an innovative biopharmaceutical company with an international footprint, released its prospectus for a secondary offering on the Hong Kong Stock Exchange this week. The company, which focuses on the research and development, manufacturing, and commercialization of recombinant proteins, antibodies, and targeted delivery therapies, reported RMB 1.534 billion (USD 225 million) in revenues and RMB 153 million (USD 22.5 million) in net profits for the previous fiscal year.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=64628\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-07T06:18:25+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-07T06:18:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/0703.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64628#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64628\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Kexing Pharmaceutical Launches HKEX Secondary Offering \u2013 Innovative Biopharma Seeks Capital to Advance Multimodal Pipeline\",\"datePublished\":\"2026-05-07T06:18:25+00:00\",\"dateModified\":\"2026-05-07T06:18:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64628\"},\"wordCount\":457,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64628#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/0703.webp\",\"keywords\":[\"Kexing Biopharm\",\"SHA: 688136\"],\"articleSection\":[\"Others\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=64628#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64628\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=64628\",\"name\":\"Kexing Pharmaceutical Launches HKEX Secondary Offering \u2013 Innovative Biopharma Seeks Capital to Advance Multimodal Pipeline - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64628#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64628#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/0703.webp\",\"datePublished\":\"2026-05-07T06:18:25+00:00\",\"dateModified\":\"2026-05-07T06:18:26+00:00\",\"description\":\"Kexing Pharmaceutical (SHA: 688136), an innovative biopharmaceutical company with an international footprint, released its prospectus for a secondary offering on the Hong Kong Stock Exchange this week. The company, which focuses on the research and development, manufacturing, and commercialization of recombinant proteins, antibodies, and targeted delivery therapies, reported RMB 1.534 billion (USD 225 million) in revenues and RMB 153 million (USD 22.5 million) in net profits for the previous fiscal year.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64628#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=64628\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64628#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/0703.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/0703.webp\",\"width\":1080,\"height\":608,\"caption\":\"Kexing Pharmaceutical Launches HKEX Secondary Offering \u2013 Innovative Biopharma Seeks Capital to Advance Multimodal Pipeline\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64628#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Kexing Pharmaceutical Launches HKEX Secondary Offering \u2013 Innovative Biopharma Seeks Capital to Advance Multimodal Pipeline\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Kexing Pharmaceutical Launches HKEX Secondary Offering \u2013 Innovative Biopharma Seeks Capital to Advance Multimodal Pipeline - Insight, China&#039;s Pharmaceutical Industry","description":"Kexing Pharmaceutical (SHA: 688136), an innovative biopharmaceutical company with an international footprint, released its prospectus for a secondary offering on the Hong Kong Stock Exchange this week. The company, which focuses on the research and development, manufacturing, and commercialization of recombinant proteins, antibodies, and targeted delivery therapies, reported RMB 1.534 billion (USD 225 million) in revenues and RMB 153 million (USD 22.5 million) in net profits for the previous fiscal year.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=64628","og_locale":"en_US","og_type":"article","og_title":"Kexing Pharmaceutical Launches HKEX Secondary Offering \u2013 Innovative Biopharma Seeks Capital to Advance Multimodal Pipeline","og_description":"Kexing Pharmaceutical (SHA: 688136), an innovative biopharmaceutical company with an international footprint, released its prospectus for a secondary offering on the Hong Kong Stock Exchange this week. The company, which focuses on the research and development, manufacturing, and commercialization of recombinant proteins, antibodies, and targeted delivery therapies, reported RMB 1.534 billion (USD 225 million) in revenues and RMB 153 million (USD 22.5 million) in net profits for the previous fiscal year.","og_url":"https:\/\/flcube.com\/?p=64628","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-05-07T06:18:25+00:00","article_modified_time":"2026-05-07T06:18:26+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/0703.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=64628#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=64628"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Kexing Pharmaceutical Launches HKEX Secondary Offering \u2013 Innovative Biopharma Seeks Capital to Advance Multimodal Pipeline","datePublished":"2026-05-07T06:18:25+00:00","dateModified":"2026-05-07T06:18:26+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=64628"},"wordCount":457,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=64628#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/0703.webp","keywords":["Kexing Biopharm","SHA: 688136"],"articleSection":["Others"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=64628#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=64628","url":"https:\/\/flcube.com\/?p=64628","name":"Kexing Pharmaceutical Launches HKEX Secondary Offering \u2013 Innovative Biopharma Seeks Capital to Advance Multimodal Pipeline - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=64628#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=64628#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/0703.webp","datePublished":"2026-05-07T06:18:25+00:00","dateModified":"2026-05-07T06:18:26+00:00","description":"Kexing Pharmaceutical (SHA: 688136), an innovative biopharmaceutical company with an international footprint, released its prospectus for a secondary offering on the Hong Kong Stock Exchange this week. The company, which focuses on the research and development, manufacturing, and commercialization of recombinant proteins, antibodies, and targeted delivery therapies, reported RMB 1.534 billion (USD 225 million) in revenues and RMB 153 million (USD 22.5 million) in net profits for the previous fiscal year.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=64628#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=64628"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=64628#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/0703.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/0703.webp","width":1080,"height":608,"caption":"Kexing Pharmaceutical Launches HKEX Secondary Offering \u2013 Innovative Biopharma Seeks Capital to Advance Multimodal Pipeline"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=64628#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Kexing Pharmaceutical Launches HKEX Secondary Offering \u2013 Innovative Biopharma Seeks Capital to Advance Multimodal Pipeline"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/0703.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64628","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=64628"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64628\/revisions"}],"predecessor-version":[{"id":64631,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64628\/revisions\/64631"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/64630"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=64628"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=64628"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=64628"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}